{Reference Type}: Case Reports
{Title}: Primary lung cancer with pulmonary alveolar proteinosis treated with immune checkpoint inhibitor: A case report.
{Author}: Horie M;Nakashima K;Amano Y;Shiratsuki Y;Murakami K;Isobe T;Tsubata Y;
{Journal}: Respir Med Case Rep
{Volume}: 47
{Issue}: 0
{Year}: 2024
暂无{DOI}: 10.1016/j.rmcr.2023.101976
{Abstract}: Primary lung cancer with pulmonary alveolar proteinosis (PAP) is a rare condition. We present a case of a patient with primary lung cancer with PAP treated with an immune checkpoint inhibitor (ICI). A 62-year-old man was diagnosed with autoimmune PAP 8 years prior to current admission. Lung adenocarcinoma was found in his right lung, and platinum-based chemotherapy was administered, followed by atezolizumab. He experienced disease progression after atezolizumab treatment, whereas ICI-induced pneumonia or exacerbation of PAP did not occur. This indicates that ICI may be safely used in patients with primary lung cancer with PAP.